Rosenberg M R, Green M
Department of Medical Education, Providence Medical Center, Portland, Ore.
Arch Intern Med. 1989 Sep;149(9):1927-31. doi: 10.1001/archinte.149.9.1927.
The purpose of this study was to evaluate options available for the treatment of neuroleptic malignant syndrome. We conducted a computer search of English-language literature using a Medline database and review of bibliographies of identified articles. Sixty-four case reports containing sufficient data about patients' demographics and clinical response to therapy to allow evaluation were combined with three previously unreported cases. The mean time to clinical response was 6.8 days when supportive measures alone were used in the treatment of neuroleptic malignant syndrome. The addition of dantrolene (response time, 1.15 days) or bromocriptine (response time, 1.03 days) significantly shortened the time to clinical response. We conclude that the addition of either dantrolene or bromocriptine to conservative measures decreases the time to clinical response. A randomized trial would address potential case selection biases.
本研究的目的是评估可用于治疗抗精神病药恶性综合征的方法。我们使用Medline数据库对英文文献进行了计算机检索，并查阅了已确定文章的参考文献目录。将64篇包含足够患者人口统计学数据和治疗临床反应数据以供评估的病例报告与3例先前未报告的病例相结合。在使用支持性措施单独治疗抗精神病药恶性综合征时，临床反应的平均时间为6.8天。添加丹曲林（反应时间为1.15天）或溴隐亭（反应时间为1.03天）显著缩短了临床反应时间。我们得出结论，在保守治疗措施中添加丹曲林或溴隐亭均可缩短临床反应时间。一项随机试验将解决潜在的病例选择偏倚问题。
